

**CREIGHTON UNIVERSITY
INSTITUTIONAL BIOSAFETY COMMITTEE**

IBC MEETING MINUTES

MEETING LOCATION

Zoom (via Invitation)

MEETING DATE and TIME

10-Apr-2026 at 02:00 PM

Institutional Biosafety Committee

2500 California Plaza

Omaha, NE 68178-0125

T: 402.280.2126 | E: IBC@creighton.edu

creighton.edu | creighton.edu/researchservices

ATTENDANCE	
VOTING MEMBERS PRESENT:	
Richard Goering, PhD Vice Chair, Scientist (Medical Microbiology & Immunology)	Aurijit Sarkar, PhD Member, Scientist (Pharmaceutical Sciences)
Nicholas Streck, PhD Member, Scientist (Biomedical Sciences, Virology, & Immunology)	Marisa Zallocchi, PhD Member, Scientist (Biomedical Sciences)
Rima El-Herte, PhD Member, Scientist (Infectious Disease)	Christopher Austin, MS Member, Scientist, Community Representative
STAFF MEMBERS PRESENT:	
Teri Prentis, BA <i>IRB Administrator</i>	
Stuart Martens, JD <i>Legal</i>	
Shannon Walsh, MS <i>Research Compliance Auditor</i>	

Attended in Person: None – virtual meeting.

Attended via Zoom: All attendees were present via Zoom.

The IBC has 10 voting members. Six members, including at least one community representative, are required to conduct business.

A quorum was met and Dr. Goering called the meeting to order at 2:11 PM

The Chair asked whether any members of the Committee had a conflict of interest for any item on the meeting agenda. No members reported a conflict of interest.

The Chair asked whether members of the Committee had received all necessary materials to complete their reviews for this meeting. All members confirmed they received all necessary materials to complete their reviews for this meeting.

The IBC Administrator reviewed the CITI training, documentation, and disclosure requirements for members of the IBC. No members present at this meeting had training, documentation, and/or disclosure deficiencies. All present members were therefore eligible to vote.

The Chair will vote only as necessary to maintain quorum or to break a tie in voting.

REVIEW AND APPROVAL OF PREVIOUS MINUTES

The Committee reviewed and approved the **08-Aug-2026 IBC Minutes** as written.

Total Vote Count	For	Against	Abstained	Absent	Recused
6	5	0	1	0	0

The Chair of this meeting, Richard Goering, abstained.

The Committee reviewed and approved the **12-Sep-2025 IBC Minutes** as written

Total Vote Count	For	Against	Abstained	Absent	Recused
6	5	0	1	0	0

The Chair of this meeting, Richard Goering, abstained.

The Committee reviewed and approved the **10-Oct-2025 IBC Minutes** as written

Total Vote Count	For	Against	Abstained	Absent	Recused
6	5	0	1	0	0

The Chair of this meeting, Richard Goering, abstained.

The Committee reviewed and approved the **14-Nov-2025 IBC Minutes** as written.

Total Vote Count	For	Against	Abstained	Absent	Recused
6	5	0	1	0	0

The Chair of this meeting, Richard Goering, abstained.

The Committee reviewed and approved the **13-Feb-2026 IBC Minutes** as written.

Total Vote Count	For	Against	Abstained	Absent	Recused
6	5	0	1	0	0

The Chair of this meeting, Richard Goering, abstained.

REVIEW OF PRIOR BUSINESS

No review of prior business.

POLICY APPROVALS, ANNOUNCEMENTS, EDUCATION

- a. EHS-25-0585-01 (Hui Hong) Select Agent initial application approved by Chair after conditions on 05-Mar-2026

- b. EHS-22-0506-03 (Jason Bartz) Infectious Agents continuation approved by Chair after conditions on 24-Mar-2026
- c. EHS-25-0558-03 (Ann Aindow) Non-exempt modifications (personnel only) approved by Chair on 6-Apr-2026

COMMITTEE REVIEW

Submission Number: EHS-22-0533-03

Title: 231 Characterization of clinical isolates of SARS-CoV-2

Principal Investigator: Michael Belshan

Submission Type: Continuation

Type of Registration: Infectious Agents Registration

Determination: Approved

Determination Date: 10-Apr-2026

Expiration Date: 09-Apr-2029

Total Vote Count	For	Against	Abstained	Absent	Recused
6	5	0	1	0	0

The Chair of this meeting, Richard Goering, abstained.

Agents:	SARS-CoV-2; nasopharyngeal samples containing SARS-CoV-2
Agent Risk Group:	RG-2
NIH Guidelines category of r/s NA research, if applicable:	N/A

Summary: The overall aim of our studies is to characterize the genetic and biochemical properties of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus isolates from the Midwestern United States. SARS-CoV-2 is the etiologic agent of COVID-19. The purpose of this study is to isolate and sequence viruses from positive clinical specimens from the Midwestern United States and perform whole viral genome sequencing to understand the evolution and epidemiology of SARS-CoV-2. Nasal pharyngeal samples were obtained to investigate the genetic and molecular properties of SARS-CoV-2 from the Midwest region of the United States. All work is done in BSL-2+ facility following methods outlined in Belshan Lab BSL Guidelines. PPE. Samples containing virus will only be opened within the BSL cabinet, and all virus work will be performed in a BSL cabinet. SARS-CoV-2 containing samples to be discarded will be inactivated and destroyed by dilution in 10% bleach, and subsequent sterilization in an autoclave.

Discussion: There were no concerns raised. There was no discussion. The Committee voted to approve continuation for another three years.

All required training per institutional policy is complete for all individuals listed on this registration.

PUBLIC COMMENTS

There were no public comments.

**THIS MEETING ADJOURNED AT 02:11 PM
END OF COMMITTEE REVIEW**

Next meeting is tentatively scheduled for 08-May-2026 at 2 PM.

END REPORT